Eculizumab (Soliris; Alexion), a C5 inhibitor preventing cleavage into C5a and C5b, is widely considered the first-line therapy for high-risk TA-TMA.
Hayden Mitteer, PharmD Candidate
Advertisement
Articles by Hayden Mitteer, PharmD Candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
3
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Advanced NSCLC
4
FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer
5